# Mineralys Therapeutics

Type: Company (MLYS)

Source: GetYourBrief — https://getyourbrief.com/entity/mineralys-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/mineralys-therapeutics

## Timeline

- **2026-12-22**: Lorundrostat PDUFA Date — Target date for FDA decision on Mineralys' lead product candidate.
- **2026-06-01**: Nektar Phase 3 Launch — Nektar plans first patient randomization for its Atopic Dermatitis program.
- **2026-03-12**: Q4 2025 Earnings — Both Mineralys and Vuzix report year-end financial results and 2026 guidance.
- **2026-03-12**: Mineralys NDA Acceptance — FDA accepts Mineralys' NDA for lorundrostat for uncontrolled hypertension.
- **2026-03-09**: FDA NDA Acceptance — FDA formally accepts Mineralys Therapeutics' application for Lorundrostat.
- **2026**: PDUFA Goal Date — Expected timeframe for the FDA's final decision on Lorundrostat commercialization.
- **2025-12-31**: EHang Record Deliveries — EHang closes Q4 with 100 eVTOL units delivered and first GAAP profit.
- **2025-12-01**: HeartBeam FDA Clearance — HeartBeam secures 510(k) clearance for 12-lead ECG synthesis software.

## Recent coverage (7 stories, network-wide)

### AI Integration and Automation Drive Q4 2025 Earnings Across Tech Sectors
2026-03-13 00:14:41 · Sector: ai · Sentiment: Positive · Impact: 7/10 · Sources: 15

The Q4 2025 earnings cycle reveals a significant acceleration in AI-driven operational efficiency and product innovation across healthcare, aviation, and enterprise services. Key developments include CareCloud's successful automation of patient scheduling and HeartBeam's FDA-cleared AI diagnostic software, signaling a shift from experimental AI to core revenue-generating applications.
Full story: https://getaibrief.com/story/ai-integration-automation-q4-2025-earnings-analysis

### CareCloud and HeartBeam Lead AI-Driven Transformation in Healthcare SaaS
2026-03-13 00:14:31 · Sector: saas · Sentiment: Positive · Impact: 7/10 · Sources: 15

CareCloud achieved its first profitable year since its 2014 IPO, driven by its AI Center of Excellence and strategic acquisitions. Meanwhile, HeartBeam and Vuzix are pivoting toward high-margin software and engineering services, signaling a broader trend of hardware-to-SaaS transitions.
Full story: https://getsaasbrief.com/story/carecloud-heartbeam-ai-healthcare-saas-earnings-2025

### Biotech and Deep Tech Reach Critical Inflection Points in Q4 Earnings
2026-03-13 00:13:52 · Sector: startups · Sentiment: Positive · Impact: 7/10 · Sources: 15

The Q4 2025 earnings cycle marks a pivot toward commercial maturity for high-growth ventures, highlighted by Mineralys Therapeutics' FDA filing and EHang's first GAAP-profitable quarter. These results signal a de-risking phase for investors as pre-revenue startups transition into regulated, revenue-generating entities.
Full story: https://getstartupbrief.com/story/biotech-deep-tech-q4-2025-earnings-analysis

### EHang Hits Profitability Milestone as eVTOL and AR Sectors Scale for 2026
2026-03-13 00:09:12 · Sector: space · Sentiment: Positive · Impact: 7/10 · Sources: 15

EHang (EH) achieved its first quarterly GAAP profit on record eVTOL deliveries, signaling a commercial inflection point for Advanced Air Mobility. Simultaneously, Vuzix (VUZI) reported a 76% revenue surge in smart glasses and waveguide technology, underscoring robust demand for dual-use augmented reality systems.
Full story: https://getspacebrief.com/story/ehang-vuzix-q4-2025-earnings-analysis

### Mineralys and Vuzix Q4 Earnings: Biotech Milestones vs. AR Scaling
2026-03-12 23:34:01 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments.
Full story: https://getfinancebrief.com/story/mineralys-vuzix-q4-2025-earnings-analysis

### Mineralys Therapeutics Advances Lorundrostat NDA Amid Q4 Earnings Beat
2026-03-12 23:33:25 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Full story: https://getbiobrief.com/story/mineralys-mlys-q4-2025-earnings-lorundrostat-nda

### Mineralys and Vuzix Q4 2025: Clinical Milestones and AR Adoption in Focus
2026-03-12 23:32:16 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.
Full story: https://gethealthbrief.com/story/mineralys-vuzix-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.